Article

Defective high-affinity thiamine transporter leads to cell death in thiamine-responsive megaloblastic anemia syndrome fibroblasts.

Division of Hematology/Oncology, Children's Hospital, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA.
Journal of Clinical Investigation (Impact Factor: 13.77). 04/1999; 103(5):723-9. DOI: 10.1172/JCI3895
Source: PubMed

ABSTRACT We have investigated the cellular pathology of the syndrome called thiamine-responsive megaloblastic anemia (TRMA) with diabetes and deafness. Cultured diploid fibroblasts were grown in thiamine-free medium and dialyzed serum. Normal fibroblasts survived indefinitely without supplemental thiamine, whereas patient cells died in 5-14 days (mean 9.5 days), and heterozygous cells survived for more than 30 days. TRMA fibroblasts were rescued from death with 10-30 nM thiamine (in the range of normal plasma thiamine concentrations). Positive terminal deoxynucleotide transferase-mediated dUTP nick end-labeling (TUNEL) staining suggested that cell death was due to apoptosis. We assessed cellular uptake of [3H]thiamine at submicromolar concentrations. Normal fibroblasts exhibited saturable, high-affinity thiamine uptake (Km 400-550 nM; Vmax 11 pmol/min/10(6) cells) in addition to a low-affinity unsaturable component. Mutant cells lacked detectable high-affinity uptake. At 30 nM thiamine, the rate of uptake of thiamine by TRMA fibroblasts was 10-fold less than that of wild-type, and cells from obligate heterozygotes had an intermediate phenotype. Transfection of TRMA fibroblasts with the yeast thiamine transporter gene THI10 prevented cell death when cells were grown in the absence of supplemental thiamine. We therefore propose that the primary abnormality in TRMA is absence of a high-affinity thiamine transporter and that low intracellular thiamine concentrations in the mutant cells cause biochemical abnormalities that lead to apoptotic cell death.

0 Bookmarks
 · 
91 Views
  • The Journal of Urology 04/2011; 185(4). · 3.75 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Thiamine-responsive megaloblastic anemia syndrome is a rare autosomal recessive disorder defined by the occurrence of megaloblastic anemia, diabetes mellitus, and bilateral sensorineural deafness, responding in varying degrees to thiamine treatment. We report a precedence case for the treatment of deafness associated with the typical triad of thiamine-responsive megaloblastic anemia in a 4-year-old boy who showed a poor use of preoperative hearing aids but demonstrated significant improvements in hearing ability 1 year after receiving a cochlear implant.
    Annals of Saudi medicine 34(1):78-80. · 0.71 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Mitochondria play a pivotal role in cellular metabolism and in energy production in particular. They generate cellular energy in the form of ATP by coupling the electron flux along the respiratory chain to the process of oxidative phosphorylation (OXPHOS). Depending on their energy demand, different cell types contain different amounts of mitochondria, ranging from only a few in the spermatozoon to several thousands in cells of skeletal muscle, heart and brain and, about 105 in oocytes. Defects in structures or functions of mitochondria, mainly affecting the OXPHOS system, have been shown to be involved in the pathogenesis of a variety of systemic or organ-specific manifestations (reviewed in (1)). In particular, organ systems with high energy requirements, such as the central nervous system, heart, skeletal muscle, kidney and the endocrine system are susceptible to mitochondrial dysfunction. Neurological defects such as psychomotor retardation, hypotonia or ataxia, myo-or cardiomyopathies, optic atrophy or sensorineural hearing loss are among the most frequent clinical symptoms observed in OXPHOS disorders. Because of their high metabolic activity, pancreatic I3-cells are also highly sensitive to ATP-supply defects. Diabetes mellitus is, therefore, frequently observed as one symptom in patients with complex mitochondrial disorders, in particular in those carrying mitochondria) DNA (mtDNA) mutations.
    01/2001;

Preview

Download
0 Downloads
Available from